In proteinuric patients with primary or secondary FSGS (both nephrotic and non-nephrotic), the traditional therapeutic approach consists of blood pressure control and the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (176). This evidence concerns the gene ACE and focal segmental glomerulosclerosis.